Microglial activation is an early response to brain ischemia and many other stressors. Microglia continuously monitor and respond to changes in brain homeostasis and to specific signaling molecules expressed or released by neighboring cells. These signaling molecules, including ATP, glutamate, cytokines, prostaglandins, zinc, reactive oxygen species, and HSP60, may induce microglial proliferation and migration to the sites of injury. They also induce a nonspecific innate immune response that may exacerbate acute ischemic injury. This innate immune response includes release of reactive oxygen species, cytokines, and proteases. Microglial activation requires hours to days to fully develop, and thus presents a target for therapeutic intervention with a much longer window of opportunity than acute neuroprotection. Effective agents are now available for blocking both microglial receptor activation and the microglia effector responses that drive the inflammatory response after stroke. Effective agents are also available for targeting the signal transduction mechanisms linking these events. However, the innate immune response can have beneficial as well deleterious effects on outcome after stoke, and a challenge will be to find ways to selectively suppress the deleterious effects of microglial activation after stroke without compromising neurovascular repair and remodeling.
INTRODUCTION
Stroke is a frequent cause of death and disability worldwide. In ischemic stroke, cessation of blood flow through a cerebral artery leads to energy depletion and subsequent death of cells in the ischemic territory. Both the ischemia per se and resulting cell death can induce an inflammatory response, which can in turn injure otherwise viable cells. 1, 2 The inflammatory response can also impair neurogenesis and other postischemic changes that are thought to contribute to functional recovery after stroke. [3] [4] [5] Several interventions have been shown to reduce acute ischemic cell death in animal models of stroke, 6 but these are generally ineffective if not initiated very soon after onset of ischemia. These interventions have consequently been difficult to put into clinical practice, because the vast majority of stroke patients do not present for medical care until many hours after symptom onset. By contrast, brain inflammation develops over a much slower time course, and is thus more amenable to therapeutic intervention.
The innate immune response is a triggered by a variety of signals that, unlike the adaptive immune response, do not require antibody recognition. Microglia are the resident macrophages in brain, and they play a critical role in the innate immune response. [7] [8] [9] Microglia normally display an extremely ramified appearance, but when activated assume a more amoeboid morphology and express surface markers that make them virtually indistinguishable from macrophages and circulating monocytes. Microglial activation is the initial step in the CNS inflammatory response; depending on the stimulus, this step may be followed by infiltration of circulating monocytes, neutrophils, and T-cells, and by reactive astrocytosis. phagocytosis of cell debris, remodeling of the extracellular matrix, and the release of cytokines and trophic factors. 5, 19, 20 These beneficial aspects of the microglial response are beyond the scope of the present review, but they must be considered in contemplating the net effect of manipulations that influence microglial activation. Temporal factors may be particularly crucial in this respect, because some evidence suggests that the cytotoxic aspects of inflammation are most important in the first few days after stroke, and that the salutary effects become more important later on. 5, 20 An additional caveat is that microglia do not act in isolation, but rather in concert with infiltrating immune cells from the blood stream, astrocytes, and other cells of the brain parenchyma.
Thus, our focus here on microglia is primarily an organizational approach.
Factors influencing microglial contribution to ischemic injury may be divided into three components, in analogy to a reflex loop (FIG. 1) . The first of these is an afferent limb, whereby microglia detect ischemic cell injury and related alterations in brain homeostasis; the second is a signal transduction limb, in which these signals are integrated and transduced into genomic or other signals; and the third is an effector limb, whereby microglia directly or indirectly contribute to bystander cell death. In this review we consider these components in reverse order, beginning with the efferent, cytotoxic limb.
FIG. 1.
Microglial responses to cerebral ischemia can be conceptualized in terms of three components: a sensory component, involving detection of extracellular signals by an array of cell-surface and intracellular receptors; a signal transduction component, whereby these signals influence gene expression in ways that are dependent on the intensity, duration, and types of signals detected; and an effector component, whereby numerous proinflammatory responses can be activated. For simplicity, many additional factors and interactions between factors are omitted here. AP-1 ϭ transcription factor AP-1 (activator protein 1); COX2 ϭ cyclooxygenase 2; Cx32 ϭ connexin-32 (gap junction beta-1 protein); CX3R1 ϭ fractalkine receptor; EAAT ϭ excitatory amino acid transporter; EP2 ϭ prostaglandin E2 receptor; ERK ϭ extracellular signal-regulated kinase; HMGB1 ϭ high-mobility group box 1; HSP ϭ heat shock protein; iGluR ϭ ionotropic glutamate receptor; IFN␥ ϭ interferon ␥; IL ϭ interleukin; iNOS ϭ inducible nitric oxide synthase; JNK ϭ c-Jun N-terminal kinase; MAPK ϭ mitogen-activated protein kinase; MIP ϭ microtubule interacting protein; MMP ϭ matrix metalloproteinase; mGluR ϭ metabotropic glutamate receptor; NF-B ϭ nuclear factor B; NO ϭ nitric oxide; NOX ϭ NADPH oxidase; P2X 7 ϭ P2X purinoreceptor 7; PARP-1 ϭ poly(ADP-ribose) polymerase 1; PGE2 ϭ prostaglandin E2; PKC ϭ protein kinase C; PLC ϭ phospholipase C; PPAR␥ ϭ peroxisome proliferator activated receptor ␥; TLR4 ϭ Toll-like receptor 4; TNF␣ ϭ tumor necrosis factor ␣; TNFR ϭ tumor necrosis factor receptor; TREM2 ϭ triggering receptor expressed on myeloid cells 2.
MECHANISMS OF MICROGLIAL CYTOTOXICITY IN ISCHEMIA
Microglia, like macrophages, have a repertoire of responses that facilitate rapid sequestration and killing of invading microorganisms and limit the effects of trauma and cell necrosis. 11 These responses include rapid migration, proliferation, and the release of superoxide, nitric oxide (NO), proteases, and cytokines. Some of these responses may be counterproductive after stroke and thus provide potential therapeutic targets.
Superoxide production
Superoxide is produced by the partial reduction of molecular oxygen to form O 2 ⅐ . Superoxide in turn reacts with other molecules to produce more highly reactive oxygen species, such as peroxynitrite, hypochlorous acid, carbonyl radical, and hydroxyl radical, all of which are directly cytotoxic to neurons and other cells. Superoxide and these other reactive species also promote microglial activation in a feed-forward manner. 21, 22 The production of superoxide by microglia occurs primarily by NADPH oxidase (NOX), of which several isoforms have been characterized. 23, 24 Of note, glucose availability can be rate-limiting for NADPH production, and thus for superoxide production, and this provides a mechanism by which hyperglycemia can exacerbate injury during ischemia or inflammation. 25, 26 Recent work has shown that microglia can potentiate injury to blood-brain barrier constituents (astrocytes and endothelial cells) via NOX-mediated superoxide in cell culture models of ischemia. 13 In addition, several groups have shown that mice deficient in the gp91 subunit of NOX2 have smaller infarcts than do wild-type mice, [27] [28] [29] and that outcomes from experimental cerebral ischemiareperfusion are improved with early administration of the pharmacological NOX inhibitors apocynin 29 -33 and honokiol. 34, 35 These results identify NOX as a promising target for therapeutic intervention, but it is possible that the efficacy of these treatment strategies may be due largely or in part to inhibition of NOX in cell types other than microglia. 25 There are as yet no published studies addressing the efficacy of NOX inhibitors administered at delayed time points after ischemia, in a manner selectively targeting the inflammatory response.
Nitric oxide
Activated microglia produce NO by upregulating the expression of inducible nitric oxide synthase (iNOS). Brain ischemia causes an upregulation of iNOS and increased NO production. 36, 37 The cytotoxicity of NO is thought to be due primarily to its reactive metabolite, peroxynitrite, which is formed by reaction with superoxide. 38 Pharmacological inhibition of iNOS with aminoguanidine reduces infarct volume in mice, 37 and iNOSnull mice have smaller infarcts and better neurologic outcomes than wild-type control animals. 39 Hypothermia after ischemia likewise reduces microglial iNOS expression and NO production. 40 As with NOX inhibitors, however, iNOS inhibitors have not yet been evaluated for use at delayed time points after ischemia in a manner that would provide sustained suppression of inflammation-induced NO production.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are proteases that can break down extracellular proteins, such as collagen, and are involved in extracellular matrix remodeling. Normally found in the cytosol in an inactivated state, MMPs are cleaved by proteases such as plasmin or other MMPs to their active state. 41 Some MMPs, notably MMP-9, also have direct cytotoxic effects and can disrupt the blood-brain barrier. 42 Microglia are the major source of MMP release following ischemia, especially MMP-3 and MMP-9. 43, 44 In experimental stroke models, acute MMP inhibition reduces infarct size, brain edema, and recombinant tissue plasminogen activator-induced hemorrhage, 45 and mice deficient in MMP-9 or MMP-3 have reduced ischemic injury relative to wild-type controls. 46, 47 However, prolonged inhibition of MMPs after ischemia may have deleterious effects on functional recovery, because these proteases are important in neurovascular remodeling after stroke. 20 Minocycline protects against permanent cerebral ischemia in wild-type but not in MMP-9 -deficient mice, suggesting this as a mechanism by which minocycline exerts its neuroprotective effect. 48 Doxycycline also suppresses postischemic MMP-9 activity, 49 and both direct and indirect pathways for MMP-9 inhibition by minocycline and doxycycline have been described.
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Glutamate
Microglia can release glutamate through hemichannels, by reversal of glutamate uptake, and by upregulating glutaminase. 52 This release can produce neuronal death in culture and in ex vivo slice preparations. 52, 53 Glutamate release from microglia might thus contribute to ischemic brain injury, 54 but the effect of glutamate release from microglia is likely to be small relative to the effects of neuronal glutamate release and failure of astrocyte glutamate reuptake that occur during brain ischemia. Nonetheless, glutamate release from chronically activated microglia in the postischemic period could contribute to delayed neuronal death at infarct margins or after transient ischemia. Microglia can also take up glutamate, 55 but the net effect of this uptake relative to rapid, high-capacity astrocyte uptake is unknown.
Chemokines, cytokines, and trophic factors
Resting microglia release a variety of chemokines and cytokines, and the pattern of this release is dramatically altered after ischemia. 56 These factors function primarily as intercellular signaling molecules, and many have feedforward effects in driving the inflammatory response. Some, such as tumor necrosis factor ␣ (TNF␣), can also have direct cytotoxic effects 57 and promote disruption of the blood-brain barrier. 58 Microglia also release a number of neurotrophic factors, and there is evidence that trophic factors released from microglia are important in maintaining neuronal integrity after an ischemic insult. 59 -61 These observations highlight the complexity of the microglial innate immune response and the potential problems inherent in unselective inhibition of this response.
SIGNALING PATHWAYS DRIVING MICROGLIAL ACTIVATION IN ISCHEMIA
Microglia continuously monitor the extracellular space and adjacent cell surfaces for evidence of homeostatic perturbations. Almost any change in these is capable of inducing microglial activation, but certain factors appear to be of salient importance in ischemia and have discrete signaling pathways.
Purinergic receptors
Purinergic receptors have emerged as key sensors of brain injury. Of the numerous purinergic receptors identified, P2X 7 and P2Y 12 have been best characterized in this respect, but P2X 4 and adenosine receptors also contribute. 62 The P2X 7 receptors are expressed by resting microglia, and this expression is upregulated after brain injury. 63 Activation of P2X 7 receptors triggers microglia proliferation, 64, 65 superoxide production, 66 release of interleukin 1␤ (IL-1␤), 67, 68 and release of TNF␣. 64, 69 However, microglia also exhibit reduced phagocytosis during P2X 7 receptor stimulation. 70 Activation of microglial P2Y 12 receptors leads to process extension and subsequent microglia migration toward the stimulus source through interactions with integrin-␤1. 71, 72 Both P2X 7 and P2X 12 receptors respond to ATP as an endogenous agonist. It has been postulated that ATP is released into the extracellular space as a result of tissue injury, but it is unlikely that this occurs simply as a passive result of membrane disruption. Ischemic injury, for example, produces energy failure and ATP depletion, and ATP released into brain extracellular space is quickly degraded by exonucleases. 73 Thus, an active, ongoing release of ATP is more likely to be the stimulus source acting on microglial purinergic receptors. A feedforward, ATP-induced release of ATP from astrocytes is one possible mechanism. 74 Experimental studies have shown that P2X 7 antagonists reduce injury and postinjury inflammation when administered acutely after spinal cord injury 75 or stroke. 76 However, there is also report of stroke exacerbation by P2X 7 antagonists. 77 These studies are intriguing, but their interpretation is complicated because these antagonists may also affect other purinergic receptors at the concentrations achieved in vivo, and cell types other than microglia express P2X 7 and other purinergic receptors.
Toll-like receptors and high-mobility group box 1 protein
Innate immune responses are frequently mediated by Toll-like receptors (TLRs), a family of transmembrane proteins involved in the recognition of and defense of microbials. Toll-like receptors are found on a several cell types in the CNS, including microglia. Microglia are activated following stimulation of TLR4, which in turn leads to the upregulation of several proinflammatory genes. Work in neonatal mice suggests that TLR4 is necessary for microglial activation following hypoxia/ ischemia, 14 and several groups that have shown that TLR4-deficient mice have better neurological outcomes following experimental stroke. 78 -81 How TLRs are activated in stroke is not precisely known, but endogenous ligands include hyaluronic acid, fibronectin, heat shock proteins (HSP), and heparin sulfate. In stroke models, HSP60 has been shown to activate TLR4 and contribute to brain injury. 82 Toll-like receptors have also been implicated in the phenomenon of tolerance, whereby stimulation of one or more of these receptors with ligands such as lipopolysaccharide (TLR4) or CpG (TLR9) led to protection from subsequent lethal insults. [83] [84] [85] [86] Mice lacking these receptors failed to achieve tolerance, 83 but the role for microglia in this process remains to be established.
The high-mobility group box 1 (HMGB1) protein is another endogenous agonist at TLR2 and TLR4 receptors. HMGB1 is normally localized to the nucleus in all cells, where it functions as a nuclear protein involved in enhancing transcription. 87 However, necrotic cell death induces active release of HMGB1, 88, 89 and antibody to HMGB1 reduces injury in experimental stroke. 90 
Chemokine and cytokine receptors
Chemokines are a family of regulatory polypeptides with roles in cellular communication and inflammatory cell recruitment. Fractalkine, a neuronally expressed chemokine, acts through its G-protein-coupled receptor CX3C. Following ischemia, its expression has been localized to viable neurons in the infarct periphery as well as some endothelial cells. 91 Fractalkine is constitutively expressed in the CNS, mainly by neurons, and is upregulated and released in response to proinflammatory stimuli. 92 Expression of the fractalkine receptor, CX3CR1, is observed only on microglia and macrophages, suggesting that fractalkine is involved in neuron-microglial signaling. 91 Mice deficient in fractalkine 93 or its microglial receptor 94 have smaller infarct sizes and better functional outcomes. CX3CR1 antagonists are currently under development.
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Prostaglandin receptors and nonsteroidal anti-inflammatory drugs Prostaglandins (PGs) are potent autocrine and paracrine oxygenated lipid molecules. Prostaglandins, especially PGE2, contribute to cell injury in ischemia and in some neurodegenerative diseases. PGE2 signaling is mediated by interactions with four distinct G protein-coupled receptors, EP1-EP4, which are differentially expressed on neuronal and glial cells throughout the CNS. Activation of EP2 has been shown to mediate microgliainduced paracrine neurotoxicity. 97 There are currently no selective EP2 antagonists available, but the production of PGE2 can be inhibited by a variety of compounds such as aspirin and indomethacin, which are termed nonsteroidal anti-inflammatory drugs (NSAIDs). 98 NSAIDs have been shown to suppress the effector molecules produced by lipopolysaccharide activation of microglia primary cultures. In addition, primary microglia cell cultures prepared from EP2 Ϫ/Ϫ mice exhibit reduced secretion of proinflammatory cytokines and chemokines. 99 Thus, EP2 antagonists appear to be an attractive target for suppressing deleterious effects of inflammation after stroke. A complicating factor, however, is that antagonists at neuronal EP2 receptors can impair neuronal survival.
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Glutamate receptors
Microglia in culture express several subtypes of glutamate receptors, including subunits of the AMPA receptor, kainate receptor, and NMDA receptor. 100 -104 They also express all three groups of metabotropic receptors: group I (mGluR5), 105 group II (mGluR2 and 3), 106, 107 and group III (mGluR4, 6, and 8). 106, 108 Stimulation with either glutamate or with ionotropic glutamate receptor agonists induces microglial proliferation, morphological changes characteristic of microglial activation, and release of IL-1␤, TNF␣, NO, and ATP. 100, 101, 104, 109 Conversely, activation of most mGluR types inhibits microglial inflammatory responses, 107,110 -112 with the exception that mGluR2 activation promotes microglial neurotoxicity. 106, 107 Microglia expression of glutamate receptor subtypes in vivo has not been extensively characterized, but protein expression of mGluR1, mGLuR2/3, and mGluR8 has been reported in microglia surrounding human multiple sclerosis lesions, 113 and expression of ionotropic glutamate receptors has been detected in reactive microglia in damaged areas of the hippocampus following ischemia. 114 The acute administration of an mGluR5 agonist after experimental stroke or spinal cord injury is neuroprotective, 115, 116 and an mGluR5 agonist was also shown to reduce microglial activation in the spinal cord injury study, 116 suggesting that the neuroprotective effect of these agents may be attributable to the suppression of microglial activation.
TREM2
TREM2 is a newly identified molecule involved in innate immunity. It was originally characterized by its ability to bind pathogens such as bacteria and initiate phagocytosis. 117 It has been described on activated macrophages and microglia, 118 -120 and binds to one or more ill-defined ligands on eukaryotic cells including neurons and astrocytes. [121] [122] [123] More recent work suggests that one such ligand might be HSP60, 122 a mitochondrial stress protein that can move to the cell surface under appropriate conditions. 124 Stimulation of HSP60 stimulates phagocytic activity of TREM2 expressing microglia, but not of TREM2 deficient microglia. 122 When bound to a ligand, TREM2 engages its adapter protein, DAP12, which then recruits and activates the tyrosine kinase Syk, 120, 125, 126 leading to downstream signaling through pathways including phosphatidylinositol 3-kinase (PI3K), phospholipase C␥1, and p44 -p42 extracellular signal regulated kinase (ERK), but not through classical inflammatory pathways such as nuclear factor B (NF-B) and the p38 stress-activated protein kinase. 127, 128 TREM2 has been shown to mediate phagocytosis of apoptotic neurons.
121 TREM2 binding activates microglia to phagocytose injured cells without stimulating a typical inflammatory response or the release of reactive oxygen species. Conversely, loss of TREM2 impairs phagocytosis and promotes inflammation. 119 Blockade of TREM2 using a monoclonal antibody in experimental autoimmune encephalomyelitis led to exacerbation of immune responses with increased demyelination and worsened neurological function. 129 Although it has not yet been reported in brain ischemia models, these findings suggest that TREM2 may similarly regulate microglial phagocytosis and inflammatory responses in postischemic brain.
Zinc
Zinc is involved in the pathogenesis of several diseases affecting the CNS. 130 In mammalian brain, zinc is concentrated in the presynaptic vesicles of a subset of glutamatergic axon terminals. 131 These axon terminals are distributed throughout the forebrain, and are particularly dense in hippocampus and in cerebral cortex. 132, 133 Vesicular zinc is released into the extracellular space in a calcium-dependent manner during normal neuronal activity, 134, 135 and is massively released, along with protein-bound zinc, in many pathological conditions. 130, 136 Treatment with zinc chelators has been shown to reduce neuronal death in animal models of cerebral ischemia, trauma, hypoglycemia, and neurodegenerative disorders. [137] [138] [139] [140] [141] [142] These effects may be due in part to suppression of zinc-mediated microglial activation. Zinc has been shown to induce activation of microglia in culture and in brain, and injection of the zinc chelator CaEDTA prevents ischemia-induced microglial activation. 22 The mechanism of this effect appears linked to the more general effect of oxidant stress on microglial and macrophage activation. 21 Zinc has been shown to upregulate NADPH oxidase in these cells, and the effect of zinc on microglial activation is blocked in the absence of NADPH oxidase activity. 22 The effect of zinc is also blocked by inhibiting activation of poly(ADP-ribose) polymerase 1 (PARP-1) or translocation of NF-B translocation, thus linking the zinc effect to established pathways of microglial activation.
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SIGNAL TRANSDUCTION EVENTS LINKING STIMULI TO MICROGLIAL ACTIVATION
Microglia responses to activating stimuli are modulated by the type, intensity, duration, and combination of stimuli present. 11 These factors are integrated through several signal transduction pathways to influence changes in gene expression. Interventions that block these signal transduction pathways are among the most effective agents available for suppressing microglial activation. Microglial activation is undoubtedly also influenced by one or more processes other than altered gene expression, but much less is presently known about these pathways in the setting of brain ischemia.
Mitogen-activated protein kinase (MAPK) cascade
Mitogen-activated protein kinases play an important role in transducing stress-related signals through a cascade of intracellular kinase phosphorylation and transcription factor activation. 143, 144 Three interlinked signaling pathways are activated by cerebral ischemia: the stress-activated protein kinases/c-Jun N-terminal kinases (SAPK/JNK), the p38 MAPKs, and the extracellular signal-regulated kinases (ERKs). 144 -146 All three of these pathways have been described in activated immune cells, including microglia. p38 MAPK promotes the stabilization and enhanced translation of mRNAs encoding proinflammatory proteins.
147 Activated (phosphorylated) p38 has been demonstrated in microglia in animal models of brain ischemia, 146, 148, 149 and pharmacological inhibition of p38 with the compound SD-282 decreased the number of activated microglia in ischemic brain. 150 The MAPK/ ERK signaling pathway may also regulate inflammation through its effects on PARP-1 activation, which (as detailed later in this review) is an important modulator of proinflammatory gene expression. 151 Pharmacological inhibition of both the p38 152, 153 and the MAPK/ERK 154 signaling pathways improves outcomes in a mouse model of ischemia-reperfusion, but the extent to which these effects are due to reduced inflammation has not been established.
NF-B and AP-1
NF-B is a dimeric transcription factor consisting of subunits of the Rel family. 155 The most common form of NF-B is a heterodimer composed of Rel A (p65) and p50. NF-B is normally located in the cytoplasm bound to its endogenous inhibitor protein, known as IB. Phosphorylation of IB by IB kinase (IKK) leads to IB phosphorylation, ubiquitination, and degradation. This liberates NF-B and allows it to translocate to the nucleus, where it binds to specific domains (the B domains) of gene promoter regions. Many genes involved in inflammation contain functional B domains, including TNF-␣, intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), iNOS, and IL-6.
155 NF-B also drives microglial morphological activation. 22 Mice deficient in the NF-B p50 subunit have reduced brain injury after experimental stroke. 156 Similar observations were made using deletion of the IB kinase. 157 In global ischemia, neuronal damage was significantly attenuated by introducing NF-B decoy oligodeoxynucleotides into rat brain neurons through the carotid artery. 158 Others, however, have observed deleterious effects of NF-B inhibition: constitutive activation of IB kinase to promote nuclear translocation of NF-B increased infarct size, 157 and rats given diethyldithiocarbamate, an NF-B inhibitor, also had larger infarct size, compared with controls. 159 The reasons for these discrepancies are not clear, but may stem from the fact that NF-B has prosurvival effects in neurons and other cell types. 160 Nevertheless, microglial NF-B activation in brain ischemia appears to be largely neurotoxic.
AP-1 is another transcription factor known to promote microglial activation. AP-1 is a heterodimer comprised of c-Fos and c-Jun family proteins, which form dimers consisting of various subunits depending on the circumstances. These dimers bind to specific DNA regions, the AP-1 domains, which regulate the expression of a number of target genes (collectively referred to as late response genes). 161 Like NF-B, the activation of AP-1 in microglia drives a proinflammatory response and the release of several cytotoxic agents.
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PPAR␥
The peroxisome proliferator activated receptor ␥ (PPAR␥) is a ligand-activated transcription factor that forms heterodimers with retinoid X receptor in the cytosol, translocates to the nucleus, and binds to PPAR response domains in promoter regions of target genes. Target gene transcription may be either induced or suppressed by PPAR␥ binding, depending on whether it is bound to an activating ligand. 165 The primary endogenous ligand for PPAR␥ is 15-deoxy-prostaglandin J 2 (15d-PGJ2), and several synthetic ligands such as thiazolidinedione have now been generated. PPAR␥ expression in healthy brain is most prominent in glial cells, 166 but occurs also in neurons. 167, 168 PPAR␥ expression in primary microglia cells is downregulated upon microglial activation, but introduction of the natural ligand, 15d-PGJ2, restores PPAR␥ expression and PPAR␥ DNA binding. 169 Treatment with either natural or synthetic PPAR␥ ligands suppresses iNOS and MHC class II expression, inhibits COX-2 activity, and suppresses synthesis of PGE2, NO, TNF␣, IL-1␤, and IL-6 by cultured microglia. 169 -172 The anti-inflammatory effect of 15d-PGJ2 is mediated at least in part through suppression of STAT expression and a resultant increase in IB expression, leading to decreased nuclear translocation of NF-B and thus decreased NF-B transcription activity. 169, 173 Moreover, at high concentrations 15d-PGJ2 induces apoptosis in activated microglia. 172 Cerebral ischemia increases PPAR␥ expression in neurons and microglia, but at the same time DNA binding of PPAR␥ is reduced. 174 DNA binding is restored by PPAR␥ ligands, 170, 174, 175 and these agents have been shown to reduce ischemic injury in rodent stroke models. 176 Treatment with PPAR␥ ligands reduces microglia and macrophage activation and migration to the periinfarct regions, 177, 178 attenuates the expression of ICAM-1, MMP-9, IL-1␤, COX-2, TNF␣, and iNOS, and suppresses production of reactive oxygen species.
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Nurr1 and progranulin
Nurr1 is considered an orphan nuclear receptor. Nurr1 exerts anti-inflammatory effects by docking to NF-Bp65 on target inflammatory gene promoters in a signaldependent manner. Subsequently, Nurr1 recruits the CoREST corepressor complex, resulting in clearance of NF-B p65 and transcriptional repression. 180 Reduced Nurr1 expression results in exaggerated inflammatory responses in microglia. 180 Progranulin is similarly expressed by macrophages and by microglia in brain. Macrophages from progranulin-deficient mice release less IL-10 and more inflammatory cytokines when exposed to bacterial lipopolysaccharide. Progranulin-deficient macrophages and microglia are cytotoxic to hippocampal cells in vitro, and progranulin-deficient hippocampal slices are hypersusceptible to deprivation of oxygen and glucose. 181 The role of Nurr1 and progranulin in postischemic inflammation has not been reported.
Glucocorticoids
Glucocorticoids are endogenous immunosuppressants and are also widely used as pharmacological agents. Glucocorticoids bind to a cytoplasmic receptor that then alters gene expression in at least two ways. One way is by binding directly to DNA and acting as a transcription factor, promoting expression of proteins such as protein inhibitor of NF-B. A second way is by binding to and interfering with actions of other transcription factors, such as NF-B and AP-1. 182 Glucocorticoids can suppress ischemia-induced microglial activation in vivo 183 and prevent microglia from inducing T-cell proliferation and Th1 responses. 184 However, this anti-inflammatory effect has not been shown to consistently reduce brain injury in experimental studies, and in some studies it worsened injury. 185 These discrepancies may be due to other effects of glucocorticoids, such as potentiation of excitotoxicity and impaired glucose transport into neurons. 186, 187 There have been 22 clinical studies of glucocorticoid use in brain ischemia. A Cochrane review of seven of these trials that met prespecified criteria indicated that there was insufficient evidence to support their use.
188
Other factors that influence proinflammatory gene transcription Several agents with neuroprotectant effects have been associated with NF-B blockade as a mechanism of action. These include HSP-70, pyruvate, sirtuins, PARP inhibitors, and minocycline.
Heat shock protein 70. A member of the stressinduced protein family, heat shock protein-70 (HSP-70) was originally identified as a chaperonin involved in the refolding of denatured proteins. 189 Several studies have shown a protective role of HSP-70 in brain injury models, and it was subsequently shown that HSP-70 also suppresses ischemia-induced microglial activation and has anti-inflammatory effects in brain ischemia. 190 This effect extends beyond ischemia, in that HSP-70 overexpression also inhibits bacterial lipopolysaccharide-induced cytokine production. 191 HSP-70 is induced in a variety of CNS cells including microglia following experimental stroke. 192 Using cocultures of astrocytes and microglia, HSP-70 transgenic microglia cultured with wild-type astrocytes experienced less injury to oxygen glucose deprivation (OGD) than did wild-type microglia cultured with wild-type astrocytes. 193 In a transgenic mouse model of HSP-70 overexpression, protection from experimental stroke was associated with decreased microglial activation. 193 Protein binding studies suggest that this is due to HSP-70 binding to the NF-B complex and blocking IB phosphorylation. 193 This anti-inflammatory may be due to the ability of HSP-70 to inhibit NF-B activation. HSP-70 can interact with IKK, thereby preventing IB phosphorylation and activation. 193, 194 Glial cells exposed to heat shock or transfected with HSP-70 showed less nuclear NFB translocation and less iNOS expression (NFB-regulated protein) when treated with bacterial lipopolysaccharide. 195 Similarly, in brain inflammation elicited by bacterial lipopolysaccharide and cytokine injection, prior heat stress led to less microglial activation and less NFB activity.
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Pyruvate. A final metabolite in glycolysis, pyruvate has recently been shown to have salutary effects in brain ischemia. [197] [198] [199] [200] The mechanism of this protective effect is unclear, but it has been correlated with reduction in microglial activation and suppression of proinflammatory cytokines following focal cerebral ischemia. At the in vitro level, ethyl pyruvate (a prodrug form of pyruvate with improved brain penetrance) was found to inhibit NF-B activation in both cultured microglia and RAW 264.7 cells through a modification of the p65 subunit. [201] [202] [203] Ethyl pyruvate also reduced mortality and reduced circulating levels of HMGB1 in a model of lethal sepsis. 202 Further, pyruvate was also shown to inhibit microglial NF-B activation in rats given bacterial lipopolysaccharide, which causes transient microglial activation independent of any cell death. 200 Thus, pyruvate may directly inhibit microglial activation.
Sirtuins. The sirtuins belong to the class III histone deacetylase family and include seven members, SIRT1-7. Sirtuins require NAD ϩ as a cofactor to deacetylate lysine residues on histones and other substrates, including NF-B. SIRT1 deacetylation of the p65 NF-B subunit inhibits NF-B transcription complex formation. 204 Microglia overexpressing SIRT1 have reduced NF-B activity and exhibit reduced neurotoxicity upon amyloid-␤ stimulation. 205 Conversely, SIRT1 inhibition or depletion in macrophage cultures has been shown to increase MMP-9 expression and TNF␣ secretion via promotion of NF-B transcriptional activity. 206, 207 Cerebral ischemia results in altered SIRT1 protein and activity levels in brain. 208 Sirtuin activity is reduced within the first 6 hours after ischemic injury, but is then is increased at 12 and 24 hours. Resveratrol, a potent SIRT1 activator, has neuroprotective effects in cerebral ischemia, 209 -211 but whether this effect is mediated through actions on microglia remains to be established. PARP inhibitors. Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme involved in both DNA repair and transcriptional regulation. 212 PARP-1 activation can be detected in activated microglia, and PARP-1 depletion or inhibition prevents microglial morphological transformation, proliferation, migration to injury site, release of cytokines, reactive oxygen species, and MMP-9.
22,213,214 PARP-1 interacts with NF-B, AP-1, and other proinflammatory transcription factors. [215] [216] [217] PARP-1 enzymatic activity is required for NF-B-mediated gene transcription and for many of the inflammatory responses in microglia. 22, 214, 218, 219 Several PARP inhibitors are now commercially available. Most of these do not discriminate well between PARP-1 and several of the other PARP species, but studies using PARP-1 Ϫ/Ϫ cells indicate a major, though perhaps not exclusive role for the PARP-1 isoform in microglial activation. 213, 214, 220 In microglia-neuron cocultures, both PARP inhibition and PARP-1 genetic deficiency prevent the neurotoxicity resulting from TNF␣-induced microglial MMP-9 release. 214 PARP-1 also induces nuclear to cytosol translocation of HMGB1 from dying cells. 89 Neuronal HMGB1 release has shown to promote inflammation and increase ischemic injury. 88 Immunohistochemical studies of brain infarcts in human brain show PARP activation in microglia up to 3 weeks after an ischemic insult. 221 Several studies using animal models have shown a reduction in poststroke microglial activation by acute administration of PARP inhibitors, 222, 223 but this anti-inflammatory effect is difficult to interpret, given that acute administration of PARP inhibitors also has a neuroprotective effect 224 -226 that could independently reduce the subsequent inflammatory response. Nonetheless, PARP-1 inhibition begun 2 days after ischemia to selectively target the inflammatory response also reduced microglial activation and improved long-term outcomes, 227 suggesting a direct effect on poststroke inflammation in vivo.
Of note, minocycline is an extremely potent PARP-1 inhibitor, 51 and the anti-inflammatory effects of minocycline may be attributable to this effect on PARP-1. Minocycline was shown to suppress microglial activation and improve neuronal survival after brain ischemia. 228, 229 Minocycline and other PARP-1 inhibitors are entering clinical trials for treatment of stroke and other conditions.
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CONCLUSIONS
Brain inflammation develops over a time period of hours to days after ischemia onset, a time window conducive to therapeutic intervention. Effective agents are now available for blocking both the microglial receptor activation and microglia effector responses that drive the inflammatory response after stroke. Agents are also available for targeting the signal transduction mechanisms linking these events. Studies have already shown some of these agents to have beneficial effects on stroke outcome in animal models. In most of these studies, however, treatment was initiated at very short time points after ischemia, and this prevents any mechanistic distinction between agents that directly suppress microglial activation and those that suppress microglial activation only as a result of reduced cell injury. A more focused evaluation of the efficacy of these agents as anti-inflammatory drugs will require a delayed onset of treatment, in order to permit this mechanistic distinction and to more closely model treatment in the clinical stroke setting. An additional consideration is that the majority of the animal studies cited in this review used stroke models involving reperfusion after relatively short periods of ischemia. This stands in contrast to clinical stroke, in which reperfusion is more commonly delayed by many hours or days, and therefore conclusions based on animal models with short periods of ischemia may not accurately guide human therapeutics. Last, it will be important to remain cognizant of the potential beneficial effects of inflammation on stroke outcome. A primary challenge in this field will be finding ways to suppress microglial activation without negatively impacting these beneficial effects.
